A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs AMG 900 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 07 Jun 2016 Results of population pharmacokinetics presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 26 Feb 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top